性能参数

产品名称

Camrelizumab

规格

1 mg 5 mg

货号

GOY-Y2368

 含量

>97.00%

CAS

1798286-48-2

别名

N/A

化学名

N/A

分子式

N/A

分子量

分子 N/A

溶解度

N/A

储存条件

Store at -20°C

General tips

用途

仅供科研

价格

电询

详细内容

In a T cell proliferation assay using tuberculin treated peripheral blood mononuclear cells, Camrelizumab induces a T cell proliferation at an EC50 of 0.11 nM. In a similar assay measuring IFN-gamma secretion, Camrelizumab induces IFN-gamma production at an EC50 of 0.38 nM[2].

Camrelizumab (3 mg/kg) combines with apatinib (200 and 100 mg/kg) inhibits the tumor inhibition rates reached 63.1% and 87.3%, respectively in human PD-1 transgenic mice[1].

[1]. Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9(3):e002191. [2]. Jason D Lickliter, et al.A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther [3]. Caicun Zho, et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021 Mar;9(3):305-314.

.

啉 AR,99%  3,5-二氯苯酚 98%

甲基丙烯酸甲酯  >99.5%(GC)  2-氟-6-甲基吡啶 98%

正辛烷 96%  对甲基苯甲酸甲酯 99%

正丙醛 AR,97%  溴乙酸苄酯 96%

1,3-丙二醇 98%  2-溴丁酸 98%

石油醚 AR,bp 60-90 °C  乙酸仲丁酯 99%

Ilaprazole sodium5mg 10mg 25mg 50mg 100mg>98.00%Cas No. 172152-50-0C19H17N4NaO2S

Kira810 mM * 1 mL in DMSO 5mg 10mg 50mg 100mg>98.00%Cas No. 1630086-20-2C31H29ClN6O3S

LEE01110mM (in 1mL DMSO) 5mg 10mg 25mg 50mg>98.00%Cas No. 1211441-98-3C23H30N8O

LDC42972mg 5mg 10mg 25mg 50mg>98.00%Cas No. 1453834-21-3C23H28N8O

LCAHA5 mg 10 mg 25 mg 50 mg 100 mg>98.00%Cas No. 117094-40-3C24H41NO3

L18910mM (in 1mL DMSO) 5mg 10mg 25mg 50mg>98.00%Cas No. 64232-83-3C11H10N4